CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for 4d Pharma PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

4d Pharma PLC
9 Bond Court
Phone: +44 1138950130p:+44 1138950130 LEEDS, LS1 2JZ  United Kingdom Ticker: DDDDDDDD

Business Summary
4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201912/31/2018Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board David R.Norwood 48
Chief Executive Officer, Executive Director Duncan J.Peyton 45
Chief Scientific Officer, Executive Director Alexander J.Stevenson 43
4 additional Officers and Directors records available in full report.

Business Names
Business Name
DDDD
GT Biologics Ltd.
The Microbiota Co.
Tucana Health Limited

General Information
Number of Employees: 116 (As of 12/31/2018)
Outstanding Shares: 65,493,842 (As of 6/30/2019)
Stock Exchange: LON
Fax Number: +44 1618376201


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 06, 2019